Table 1.
Patient characteristics
| Overall (N = 1210) | |
|---|---|
| Stage at Initial Diagnosis | |
| 0 | 1 (0.1%) |
| I | 147 (12.1%) |
| II | 352 (29.2%) |
| III | 268 (22.1%) |
| IV | 352 (29.1%) |
| Age | |
| Mean | 64.4 years |
| Range | 28-84 years |
| Race | |
| Asian | 39 (3.2%) |
| Black or African American | 99 (8.2%) |
| Hispanic or Latino | 3 (0.2%) |
| Other Race | 129 (10.7%) |
| White | 840 (69.4%) |
| ECOG Performance Status | |
| 0 | 360 (37.2%) |
| 1 | 426 (44.0%) |
| 2 | 146 (15.1%) |
| 3 | 33 (3.4%) |
| 4 | 4 (0.4%) |
| First-Line CDK4/6i Used | |
| Palbociclib | 1067 (88.2%) |
| Ribociclib | 87 (7.2%) |
| Abemaciclib | 56 (4.6%) |
| Endocrine Partner Used | |
| Anastrozole | 59 (4.9%) |
| Exemestane | 28 (2.3%) |
| Fulvestrant | 366 (30.2%) |
| Letrozole | 745 (61.6%) |
| Tamoxifen | 12 (1.0%) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; CDK4/6i, cyclin-dependent kinases 4/6 inhibitor.